Show simple item record

dc.contributor.authorPetri, Michelle A
dc.contributor.authorAvci, Mertcan
dc.contributor.authorMagder, Laurence S
dc.date.accessioned2020-11-18T17:41:57Z
dc.date.available2020-11-18T17:41:57Z
dc.date.issued2020-11-02
dc.identifier.urihttp://hdl.handle.net/10713/14108
dc.description.abstractAmong the 785 patients included in our analysis, the prevalence of persistent lupus anticoagulant as defined by the first two patient assessments was 4.3%. Annual assessment resulted in a prevalence of 6.6%, and using all 16 assessments resulted in a prevalence of 10.5%. The prevalence was substantially higher in men than in women, and in Caucasians than in African-Americans (p<0.01 for all comparisons). The rate of thrombosis was significantly elevated among those with persistently positive lupus anticoagulant by any definition (HR ranging from 2.75 to 3.42) relative to those without persistently positive lupus anticoagulant.en_US
dc.description.urihttps://doi.org/10.1136/lupus-2020-000406en_US
dc.language.isoenen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.ispartofLupus Science & Medicineen_US
dc.rights© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.en_US
dc.subjectantibodiesen_US
dc.subjectantiphospholipiden_US
dc.subjectepidemiologyen_US
dc.subjectlupus erythematosusen_US
dc.subjectsystemicen_US
dc.titleEvaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosusen_US
dc.typeArticleen_US
dc.typeOtheren_US
dc.identifier.doi10.1136/lupus-2020-000406
dc.identifier.pmid33139453
dc.source.volume7
dc.source.issue1
dc.source.countryUnited States
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record